Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice

Clinical Cancer Research

Volumn 2, Issue 11, 1996, Pages 1851-1857

  Skrepnik, Nebojsa ^a,b   Araya, Juan C ^a,c   Qian, Zhong ^a   Xu, Haibo ^a   Hamide, John ^a   Mera, Robertino ^a,b   Hunt, Jay D ^a,b  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

AR 209; IMMUNOTOXIN; ONCOPROTEIN ANTIBODY; PSEUDOMONAS EXOTOXIN; RECOMBINANT ONCOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; EXOTOXINS; HUMANS; IMMUNOTOXINS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029808177     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cancer Facts & Figures-1995. Atlanta, GA; American Cancer Society, 1995.
2. Brown, C. C., and Kessler, L. G. Projections of lung cancer mortality in the United States: 1985-2025. J. Natl. Cancer Inst., 80: 43-51, 1988.
3. Bunn, P. A. Future directions in clinical research for lung cancer. Chest, 106 (Suppl. 6): 399S-407S, 1994.
4. Wynder, E. L., and Hoffmann, D. Smoking and lung cancer: scientific challenges and opportunities Cancer Res., 54: 5284-5295, 1994.
5. Marcus, A. C., Shopland, D. R , Crane, L. A., and Lynn, W. R. Prevalence of cigarette smoking in the United States: estimates from the 1985 current population survey. J. Natl. Cancer Inst., 81: 409-414, 1989.
6. Ihde, D. C., and Minna, J. D. Non-small cell lung cancer. Part II: treatment. In: C. M. Haskell (ed.), Current Problems in Cancer, pp. 107-154. St Louis, MO: Mosby-Year Book, Inc., 1991.
7. Spiro, S. G Prognosis and Results. In: B. Hoogstraten, B. J. Addis, H H. Hansen, N. Martini, and S. G. Spiro (eds.), Lung Tumors, pp. 163-166. Berlin: Springer-Verlag, 1988.
8. Gazdar, A F. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer (Phila.), 69: 1592-1599, 1992.
9. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor share chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
10. Nilsen, T. W., Maroney, P A., Goodwin, R. G., Rottman, F. M., Crittenden, L. B., Raines, M. A., and Kung, H-J. c-erbS activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an ami no-truncated EGF receptor. Cell, 41: 719-726, 1985.
11. neu) in human non-small cell carcinomas of the lung. Cancer Res., 50: 421-425, 1990.
12. neu expression in human lung carcinomas predicts shortened survival Cancer Res., 50: 5184-5191, 1990.
13. Shi, D., He, G., Cao, S., Pan, W , Zhang, H-Z., Yu, D., and Hung, M-C. Overexpression of the. c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol. Carcinog., 5: 213-218, 1992.
14. Tsai, C-M., Chang, K-T., Wu, L-H., Chen, J-Y., Gazdar, A., Mitsudomi, T., Chen, M-H., and Perng, R-P. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res., 56: 206-209, 1996.
15. Marks, J. R., Humphrey, P. A., Wu, K., Bettry, D., Bandarenko, N., Kerns, B-J, M., and Iglehart, J. D. Overexpression of p53 and HER-2/ neu proteins as prognostic markers in early stage breast cancer. Ann. Surg., 219: 332-341, 1994.
16. Mariani-Costantini, R., Merio, G , and Frati, L. Genomic alterations in human breast cancer: a review. Tumori, 75: 311-320, 1989.
17. Slamon, D J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E , Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
18. ERBB2 expression and the gene amplification. Cancer Res., 50: 8002-8009, 1990.
19. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867-5871, 1992.
20. Kasprzyk, P. G., Sullivan, T. L., Hunt, J. D., Gubish, C. T., Scoppa, C. A., Oelkuct, M., Bird, R., Fischer, P. H., Siegfried, J. M., and King, C. R. Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbE-2 gene amplification. Clin. Cancer Res., 2: 75-80, 1996.
21. Paget, S. Secondary growths of cancer of breast. Lancet, 1: 571-573, 1889.
22. McLemore, T L , Eggleston, J. C., Shoemaker, R. H., Abbott, B. J., Bohlman, M. E., Liu, M. C., Fine, D. L., Mayo, J. G., and Boyd, M. R. Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res., 48: 2880-2886, 1988.
23. McLemore, T. L., Liu, M. C., Blacker, P. C., Gregg, M., Alley, M. C , Abbott, B. J., Shoemaker, R. H., Bohlman, M. E., Litterst, C. C., Hubbard, W. C., Brennan, R. H., McMahon, J. B., Fine, D. L., Eggleston, J. C., Mayo, J. G., and Boyd, M. R. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res., 47: 5132-5140, 1987.
24. Boyd, M. R., Shoemaker, R. H , McLemore, T. L., Mayo, J. G., Johnston, M. R., Gazdar, A. F., Minna, J. D., and Chabner, B. A. New drug development. In: J. A. Roth, J. C. Ruckdeschel, and T. S. Weisenburger (eds.), Thoracic Oncology, Chap. 51. Philadelphia: W. B. Saunders Co., 1986.
25. Siegfried, J. M., and Owens, S. E. Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. Cancer Res., 48: 4976-4981, 1988.
26. DeMichele, M. A. A., Davis, A. L. G., Hunt, J. D., Landreneau, R. J., and Siegfried, J. M. Expression of messenger RNA for three bombesin receptor subtypes in human bronchial epithelial cells. Am. J. Respir. Cell Mol Biol., 11: 66-74, 1994.
27. Hollywood, D. P., and Hurst, H C. A novel transcription factor OB2-1 is required for overexpression of the proto-oncogene c-erbR-2 in mammary tumour cell lines. EMBO J , 12: 2369-2375, 1992.
28. Siegfried, J. M. Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line. J. Cell. Biochem., 41: 91-95, 1989.
29. Fridman, R., Kibbey, M. C., Royce, L S., Zain, M., Sweeny, T. M., Jicha, D. J., Yannelli, J. R., Martin, G. R., and Kleinman, H. K. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J. Natl. Cancer Inst., 83: 769-774, 1991.
30. Pretlow, T. G., Delmoro, C. M., Dilley, G. G., Spadafora, C. G., and Pretlow, T. P. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res., 51: 3814-3817, 1991.
31. Shinitzky, M., and Skornick, Y. Cancer immunotherapy with autologous and allogeneic vaccines: a practical overview. In: C. G. Bollack and D. Jacqmin (eds.), Basic Research and Treatment of Renal Cell Carcinoma Metastasis, pp. 95-125. New York: Wiley-Liss, 1990.
32. Hunt, J. D., Pippin, B. A , Landreneau, R. J., Jacob, W. F., Lotze, M. T., and Siegfried, J. M. Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients. J. Immunother., 14: 314-321, 1993.
33. Livingston, P. O. Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens. Curr. Opin. Immunol., 4: 624-629, 1992.
34. Oettgen, H. F., and Old, L. J. The history of cancer immunotherapy. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 87-119. Philadelphia: J. B. Lippincott Co., 1991.
35. Mullen, C. A., Coale, M. M., Levy, A. T., Stetler-Stevenson, W. G., Liotta, L. A., Brandt, S., and Blaese, R. M. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res., 52: 6020-6024, 1992.
36. Knuth, A., Wölfel, T., and zum Büschenflede, K-H. M. Cellular and humoral immune responses against cancer: implications for cancer vaccines. Curr. Opin. Immunol., 3: 659-664, 1991.
37. Pai, L. H., and Pastan, I. Immunotoxins and recombinant toxins. In: V. T DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 521-533. Philadelphia: J. B. Lippincott Co., 1995.
38. Grossbard, M L., Lambert, J. M., Goldmacher, U. S., Spector, N L., Kinsella, J , Eliseo, L., Coral, F., Taylor, J. A., Blattler, W. A., and Epstein, C. L. Anti-B4-blocked ricin: a Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol., 11: 726-737, 1993.
39. Grossbard, M L., Gribben, J G., Freedman, A. S., Lambert, J. M., Kinsella, J., Rabinowe, S. N., Eliseo, L., Taylor, J A., Blattler, W. A., and Epstein, C. L. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood, 81, 2263-2271, 1993
40. Lynch, T. J., Jr. Immunotoxin therapy of small cell lung cancer. N901-blocked ricin for relapsed small cell lung cancer. Chest, 103: 4365-4395, 1993
41. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., and Ghetie, V. A Phase I study of an anti-CD22-deglycoxylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
42. Grossbard, M. L., Freedman, A. S., Ritz, J., Coral, F., Goldmacher, U. S., Eliseo, L., Spector, N., Dear, K., Lambert, J. M., and Blattler, W. A. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a Phase I trial of daily bolus infusion. Blood, 79: 576-585, 1992.